 |
| Research article summary (published 30 Oct 2003): |
Influence of postoperative complementary treatment with lectin-standardized mistletoe extract on breast cancer patients. A controlled epidemiological multicentric retrolective cohort study.
Full Abstract
This epidemiological study was performed to evaluate the influence of postoperative complementary treatment with lectin-standardized mistletoe extract (sME) on breast cancer patients. The design (retrolective cohort analysis with parallel groups) and conduct of the study were in agreement with current standards for prospectively randomized clinical trials. A cohort of 1,248 breast cancer patients on postoperative chemo-, radio-, hormone-therapy were studied in 27 randomized centers. Patients with complementary medications other than sME were excluded from the evaluation and the final analysis was performed on data of 689 patients. From this cohort 219 patients received a complementary treatment exclusively with sME (therapy group), while 470 patients were without complementary treatment (control group). The median follow-up time was 284 days (therapy group) and 285 days (control group). The primary end-point of the study was to determine the impact of complementary sME treatment on disease- or therapy-induced adverse reactions in breast cancer patients. Imbalances for causal effects (covariates) were adjusted by propensity scores. Final evaluation was performed by estimating the linear regression between change in symptom score and propensity score with all data and using the regression line to calculate the change in symptom score expected for each patient. Tumor-associated events were evaluated by number and time until event. The safety of sME treatment was analysed in terms of number, severity, duration and outcome of adverse reactions. As compared to breast cancer patients without complementary treatment (control group), the administration of sME (therapy group) resulted in a significant reduction of adverse reactions induced by the tumor-destructive therapies (e.g. nausea, gastro-intestinal tract symptoms, depression, fatigue, mental symptoms) and prolonged relapse-free intervals, most pronounced for UICC stages IIa and IIb. The rate of sME-associated adverse reactions was 12.8%. All side-effects were mild to moderate, predominantly local skin reactions and self-limiting without therapeutic intervention. Complementary treatment of breast cancer patients with lectin-standardized mistletoe extract (sME) proved to be a well tolerated optimization of standard tumor-destructive therapies, mainly improving quality of life and relapse-free intervals in defined UICC stages.
Author information
Author/s: Schumacher, K (K); Schneider, B (B); Reich, G (G); Stiefel, T (T); Stoll, G (G); Bock, P R (PR); Hanisch, J (J); Beuth, J (J);
Affiliation: Institut fuer Biometrie, Medizinische Hochschule Hannover, Konstanty-Gutschow-Str. 8, 30625 Hannover, Germany.
Journal and publication information
Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal: Anticancer research (Anticancer Res), published in Greece. (Language: eng)
Reference: -2003 Nov-Dec; vol 23 (issue 6D) : pp 5081-7
Dates: Created 2004/02/25; Completed 2004/04/05; Revised 2007/11/15;
PMID: 14981970, status: MEDLINE (last retrieval date: 2/18/2009, IMS Date: )
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
External Links for this article
(including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MESH Headings shown below.
Related articles
These are the highest related articles currently in the database:
- [Influence of ML-1 standardized mistletoe extract on the quality of life in head and neck cancer patients]
30 Mar 2006 - Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group.
29 Nov 2004 - [Blood and tissue eosinophilia, mistletoe lectin antibodies and quality of life in a breast cancer patient undergoing intratumoral and subcutaneous mistletoe therapy] 30 May 2002
- Induction of antibodies to viscotoxins A1, A2, A3, and B in tumour patients during therapy with an aqueous mistletoe extract. 28 Aug 2002
- Suppression of growth of tumour cell lines in vitro and tumours in vivo by mistletoe lectins. 27 Feb 2006
- Development and validation of an instrument to measure the effects of a mistletoe preparation on quality of life of cancer patients: the Life Quality Lectin-53 (LQL-53) Questionnaire. 28 Feb 2004
- Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. 30 Dec 2003
- Cellular immunomodulation and safety of standardized aqueous mistletoe extract PS76A2 in tumor patients treated for 48 weeks. 28 Feb 2004
- [Problems of randomized studies in complementary medicine demonstrated in a study on mistletoe treatment of patients with breast cancer] 30 May 2004
Related Article Map
5/30/2002
3/30/2006
Higher Relevance Score (23)
Lower Relevance Score (12)
Legend: - FREE Full text Article. - Abstract only. 
- Title only. More help.
See a large map of 100+ related articles.